BioPharma Dive 21 may 2026 BioMarin notches win in study that could expand use of top-selling medicine
BioPharma Dive 20 may 2026 After raising $800M, Parabilis seeks an IPO to pursue ‘undruggable’ targets
BioPharma Dive 20 may 2026 Immunovant’s potential autoimmune ‘blockbuster’; Wave’s RNA editing update